https://www.onclive.com/view/jak-inhibitor-based-combos-and-mutation-specific-regimens-comprise-the-future-of-myelofibrosis-management
It won't be long now till the scientific community to our advertising for us, should be a hell of a ride.
Here's a recent interview with Claire Harrison, MD, FRCP, FRCPath. She was the one who accompanied Gary in the recent interim data webinar at ASH 2024.
Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis, page-59
Add to My Watchlist
What is My Watchlist?
